ELEVIDYS
Live / Applied — First extension granted (statement of use) (as of 04 Jun 2025)
What this means for you
Not registered yet, but its 08 May 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97925396
- Mark type
- Design + words
- Filed
- 08 May 2023
- Published for opposition
- 19 Nov 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs being pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prior registrations
Prosecution history
- 23 Dec 2025 — TEAS STATEMENT OF USE RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Jun 2025 — SOU EXTENSION 1 GRANTED
- 04 Jun 2025 — SOU EXTENSION 1 FILED
- 04 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 31 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 19 Nov 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Nov 2024 — PUBLISHED FOR OPPOSITION
- 13 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Oct 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 02 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Oct 2024 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 02 Aug 2024 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 02 Aug 2024 — FINAL REFUSAL E-MAILED